FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma By Ogkologos - October 27, 2025 172 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial... July 23, 2021 FDA Approves Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma March 25, 2022 Zanubrutinib’s Approval Improves Targeted Treatment for CLL January 27, 2023 Building Your Fort of Support: Tips from a Breast Cancer Social... October 27, 2021 Load more HOT NEWS Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research... EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical... 10 Ways the Inflation Reduction Act will Impact Cancer Care Adjuvant Pembrolizumab Improves QoL in Patients with High-Risk Resected Melanoma
